SKIN CANCER


Associated tags: Cancer, Skin cancer, Diagnosis, Mayo Clinic, Medical imaging, Medical device, Biopsy, Skin, Teledermatology, FDA, OTD, Food, Pharmacy, US Food Sovereignty Alliance, Telehealth, Mayo, Dermatology

Locations: USA

Telehealth Pioneer Paul Johnson Joins DeepX Health Advisory Board

Retrieved on: 
Tuesday, April 2, 2024

WASHINGTON, April 2, 2024 /PRNewswire-PRWeb/ -- DeepX Health is pleased to announce the appointment of Paul Johnson to its advisory board. Mr. Johnson brings a wealth of experience in the healthcare and technology sectors, with a proven track record of building and scaling innovative healthcare businesses.

Key Points: 
  • DeepX Health appoints healthcare industry veteran Paul Johnson to its advisory board to leverage his experience in scaling healthcare businesses.
  • WASHINGTON, April 2, 2024 /PRNewswire-PRWeb/ -- DeepX Health is pleased to announce the appointment of Paul Johnson to its advisory board.
  • Mr. Johnson was the founder and CEO of Lemonaid Health, a pioneering online healthcare company that he successfully led through an acquisition by 23andMe.
  • "As a new advisory board member, I'm excited to join DeepX Health, one of the pioneers in AI-driven cancer diagnostics," said Paul Johnson.

DeepX Diagnostics Inc.'s DermoSight Receives FDA Clearance for Teledermatology Screening of Suspect Skin Cancer Lesions

Retrieved on: 
Tuesday, June 6, 2023

WASHINGTON, June 6, 2023 /PRNewswire/ -- DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for teledermatology screening of suspect skin cancer lesions in the United States. The company is now ready to enter the US market on the back of over 180 thousand assessments in pharmacies and primary care clinics in Europe.

Key Points: 
  • DeepX Diagnostics Inc. to enter US market, having already performed over 180,000 skin lesions assessments in pharmacy and primary care to date in Europe.
  • WASHINGTON, June 6, 2023 /PRNewswire/ -- DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for teledermatology screening of suspect skin cancer lesions in the United States.
  • DermoSight is currently cleared to acquire skin lesion images for teledermatology assessment, like existing digital dermatoscopes.
  • It will help people with skin lesions of concern receive early diagnosis and effective treatment of skin cancer," said Christian Horn, the CEO at DeepX Diagnostics.

DeepX Diagnostics Inc.'s DermoSight Receives FDA Clearance for Teledermatology Screening of Suspect Skin Cancer Lesions

Retrieved on: 
Tuesday, June 6, 2023

WASHINGTON, June 6, 2023 /PRNewswire/ -- DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for teledermatology screening of suspect skin cancer lesions in the United States. The company is now ready to enter the US market on the back of over 180 thousand assessments in pharmacies and primary care clinics in Europe.

Key Points: 
  • DeepX Diagnostics Inc. to enter US market, having already performed over 180,000 skin lesions assessments in pharmacy and primary care to date in Europe.
  • WASHINGTON, June 6, 2023 /PRNewswire/ -- DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for teledermatology screening of suspect skin cancer lesions in the United States.
  • DermoSight is currently cleared to acquire skin lesion images for teledermatology assessment, like existing digital dermatoscopes.
  • It will help people with skin lesions of concern receive early diagnosis and effective treatment of skin cancer," said Christian Horn, the CEO at DeepX Diagnostics.